A close look at interventional cardiac procedures to treat obstructive hypertrophic cardiomyopathy.
Search Results for: alcohol ablation
How to Improve Alcohol Septal Ablation
Since ASA has been shown to be equally safe to myectomy, the focus should now shift from justifying the procedure toward perfecting the procedure. In particular, the need for additional procedures or repeat procedures must be reduced.
Should Alcohol Septal Ablation Be Considered for Younger Patients?
Some doctors argue that the indications for alcohol septal ablation procedures in patients with obstructed hypertrophic cardiomyopathy should be expanded to include younger patients.
Septal Reduction – Not a One Size Fits All
A recent article published in the European Journal of Cardiology Heart Failure compares septal myectomy to septal alcohol ablation. The article emphasizes that proper patient selection for either procedure is key.
Seniors Do Well After Myectomy
A recent study of Medicare patients conducted by doctors at the Cleveland Clinic found that senior citizens who underwent septal myectomy had better long term survival and did not need repeat procedures compared to those who underwent septal alcohol ablation.
Cytokinetics Teases Upcoming Phase 3 Aficamten Trial in nHCM
A Phase 3 clinical trial aimed at the non-obstructed HCM population (nHCM) appears to be planned for Cytokinetics’ next-generation myosin inhibitor, aficamten.
Longer Term Results for Mavacamten
Dr. Milind Desai of the Cleveland Clinic announced at last weekend’s AHA Meeting that after 32 weeks of mavacamten treatment, patients continued to see positive results such that 88% of patients enrolled in the study were able to avoid a septal reduction procedure.
The Future of HCM Treatment
Doctors from the University of Pennsylvania published an article describing several new and/or experimental therapies which look promising for the future.
Mavacamten vs. Septal Reduction – VALOR-HCM Trial Results Published
The VALOR-HCM trial results have just been published in the Journal of the American College of Cardiology along with an accompanying editorial from Dr. Steve Ommen of Mayo Clinic.
Could Septal Reduction Outcomes Vary by Gender?
A retrospective analysis recently published in JACC: Cardiovascular Interventions suggests that the risks of septal reduction therapy may differ for men and women.